查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602720

肌萎縮側索硬化症治療藥物市場：按治療方法、分銷管道分類 - 全球預測 2025-2030 年

Amyotrophic Lateral Sclerosis Treatment Market by Treatment (Medication, Stem Cell Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肌萎縮側索硬化症治療藥物市場規模為73442萬美元，預計2024年將達到79052萬美元，複合年成長率為7.73%，到2030年預計將達到123705萬美元。

肌萎縮側索硬化症 (ALS) 治療市場研究對各種治療解決方案進行了全面分析，旨在管理 ALS 症狀、減緩疾病進展並改善患者的生活品質。 ALS 的嚴重性強調了對 ALS 治療的需求，目前尚無明確的治療方法，這推動了對創新治療方法的迫切需求。治療通常涉及新的多學科方法，包括神經保護藥物、物理治療以及遺傳和幹細胞研究。該市場受到生物技術進步、神經學研究資金增加以及人口老化導致 ALS 患者患病率增加等因素的影響。關鍵的成長機會在於個人化醫療和基因治療，這些領域可以透過生技公司和研究機構之間的策略聯盟來發展。他們還應該考慮透過進入亞洲和南美洲開拓的市場來實現市場多元化，這些市場由於醫療基礎設施和意識的改善，對創新治療的興趣正在增加。然而，市場成長面臨挑戰，包括高研發成本、高監管障礙以及疾病進展的不可預測性，這使得衡量治療效果變得複雜。智慧財產權和仿單標示外藥品的競爭進一步限制了競爭格局。根據市場動態，ALS治療創新的未來取決於CRISPR技術和生物標記研究的突破，這將顯著提高早期檢測和治療的準確性。尋求成長的相關人員應大力投資於科學合作和以病人為中心的照護模式，以適應向個人化治療方法的典範轉移。了解市場的性質表明，患者的宣傳和教育將在重塑治療的採用和接受方面發揮關鍵作用。總之，儘管監管環境仍然複雜，但優先考慮研究和策略聯盟敏捷性的公司將處於有利地位，可以抓住 ALS 治療市場的新機會。

主要市場統計
基準年[2023] 7.3442億美元
預測年份 [2024] 79052萬美元
預測年份 [2030] 1,237.05 百萬美元
複合年成長率（%） 7.73%

市場動態：快速發展的肌萎縮側索硬化症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變肌萎縮側索硬化症藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球有大量肌萎縮性側索硬化症患者
    • 人們對 ALS 治療的認知不斷增強
  • 市場限制因素
    • ALS 治療相關的高成本
  • 市場機會
    • 活性化旨在開發新的 ALS 藥物和治療方法的研發
    • 改善各國的醫療基礎設施
  • 市場挑戰
    • ALS 治療的嚴格核准流程

波特五力：駕馭肌萎縮側索硬化症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肌萎縮側索硬化症藥物市場的外部影響

外部宏觀環境因素在塑造肌萎縮側索硬化症藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解肌萎縮側索硬化症治療藥物市場的競爭狀況

對肌萎縮側索硬化症治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣肌萎縮側索硬化症藥物市場供應商績效評估

FPNV定位矩陣是評估肌萎縮側索硬化症藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪肌萎縮側索硬化症藥物市場的成功之路

對肌萎縮側索硬化症治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地有許多人患有肌萎縮性側索硬化症。
      • 提高大眾對 ALS 治療的認知
    • 抑制因素
      • ALS 治療相關的高費用
    • 機會
      • 加強研究活動，開發 ALS 新藥和治療方法
      • 改善整個經濟領域的醫療基礎設施
    • 任務
      • ALS 藥物的嚴格核准流程
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章肌萎縮側索硬化症治療藥物市場（依治療）

  • 藥物治療
    • Edaravone
    • Riluzole
  • 幹細胞療法

第7章肌萎縮側索硬化症治療藥物市場：按分銷管道

  • 醫院藥房
  • 零售藥房

第8章北美和南美肌萎縮側索硬化症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區肌萎縮側索硬化症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲肌萎縮側索硬化症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AB Science SA
  • Amylyx Pharmaceuticals Inc.
  • Aquestive Therapeutics Inc.
  • Ascend Pharmaceuticals LLC
  • Biogen Inc.
  • Biohaven Pharmaceutical Holding Co Ltd
  • BrainStorm Cell Limited
  • Corestem, Inc.
  • Cytokinetics, Incorporated
  • F. Hoffmann-La Roche AG
  • Genervon Biopharmaceuticals, LLC
  • Hackensack Meridian Health, Inc.
  • Implicit Bioscience Ltd.
  • Ionis Pharmaceuticals, Inc.
  • ITF Pharma, Inc.
  • Kringle Pharma, Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Orion Corporation
  • Orphazyme A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi-Aventis Groupe SA
  • Sun Pharmaceutical Industries Ltd
  • Treeway BV
Product Code: MRR-AD36CD897F1B

The Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 734.42 million in 2023, expected to reach USD 790.52 million in 2024, and is projected to grow at a CAGR of 7.73%, to USD 1,237.05 million by 2030.

Amyotrophic Lateral Sclerosis (ALS) treatment market research encompasses a comprehensive analysis of various therapeutic solutions aimed at managing ALS symptoms, slowing disease progression, and improving patient quality of life. The necessity for ALS treatments is underscored by the severe nature of the disease, which currently lacks a definitive cure, prompting a critical demand for innovative therapies. Treatments typically include the use of neuroprotective drugs, physical therapies, and emerging multidisciplinary approaches that involve genetic and stem cell research. The market is influenced by factors such as advancements in biotechnology, increased funding for neurological research, and an aging population that elevates the prevalence of ALS cases. Key growth opportunities lie in personalized medicine and gene therapy, areas that can be leveraged through strategic partnerships between biotech firms and research institutions. Companies should also consider geographic diversification, tapping into underexplored markets in Asia and South America, where rising healthcare infrastructure and awareness are fostering a keen interest in innovative treatments. However, market growth faces challenges including high R&D costs, stringent regulatory hurdles, and the unpredictable nature of disease progression that complicates treatment efficacy measurement. Intellectual property rights and competition from off-label drugs further constrain the landscape. According to market dynamics, the future of ALS treatment innovation hinges on breakthroughs in CRISPR technologies and biomarker research, which could significantly enhance early detection and therapeutic precision. Stakeholders anticipating growth should heavily invest in scientific collaborations and patient-centric care models to align with the shifting paradigm toward personalized treatment approaches. Understanding market nature indicates that patient advocacy and education will play pivotal roles in reshaping treatment uptake and acceptance. In summary, while navigating regulatory landscapes remains complex, firms that prioritize agility in research and strategic alliances will better position themselves to capture emerging opportunities in the ALS treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 734.42 million
Estimated Year [2024] USD 790.52 million
Forecast Year [2030] USD 1,237.05 million
CAGR (%) 7.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amyotrophic Lateral Sclerosis Treatment Market

The Amyotrophic Lateral Sclerosis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significant number of amyotrophic lateral sclerosis patients worldwide
    • Growing awareness about ALS treatment among population
  • Market Restraints
    • High cost associated with ALS treatments
  • Market Opportunities
    • Increasing research activities to develop novel ALS drugs and treatments
    • Improved healthcare infrastructure across economies
  • Market Challenges
    • Stringent approval processes for ALS therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Amyotrophic Lateral Sclerosis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amyotrophic Lateral Sclerosis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amyotrophic Lateral Sclerosis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amyotrophic Lateral Sclerosis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amyotrophic Lateral Sclerosis Treatment Market

A detailed market share analysis in the Amyotrophic Lateral Sclerosis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amyotrophic Lateral Sclerosis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amyotrophic Lateral Sclerosis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amyotrophic Lateral Sclerosis Treatment Market

A strategic analysis of the Amyotrophic Lateral Sclerosis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amyotrophic Lateral Sclerosis Treatment Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, Amylyx Pharmaceuticals Inc., Aquestive Therapeutics Inc., Ascend Pharmaceuticals LLC, Biogen Inc., Biohaven Pharmaceutical Holding Co Ltd, BrainStorm Cell Limited, Corestem, Inc., Cytokinetics, Incorporated, F. Hoffmann-La Roche AG, Genervon Biopharmaceuticals, LLC, Hackensack Meridian Health, Inc., Implicit Bioscience Ltd., Ionis Pharmaceuticals, Inc., ITF Pharma, Inc., Kringle Pharma, Inc., Mitsubishi Tanabe Pharma Corporation, Orion Corporation, Orphazyme A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sun Pharmaceutical Industries Ltd, and Treeway B.V..

Market Segmentation & Coverage

This research report categorizes the Amyotrophic Lateral Sclerosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Medication and Stem Cell Therapy. The Medication is further studied across Edaravone and Riluzole.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant number of amyotrophic lateral sclerosis patients worldwide
      • 5.1.1.2. Growing awareness about ALS treatment among population
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with ALS treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research activities to develop novel ALS drugs and treatments
      • 5.1.3.2. Improved healthcare infrastructure across economies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent approval processes for ALS therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Medication
    • 6.2.1. Edaravone
    • 6.2.2. Riluzole
  • 6.3. Stem Cell Therapy

7. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies

8. Americas Amyotrophic Lateral Sclerosis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AB Science SA
  • 2. Amylyx Pharmaceuticals Inc.
  • 3. Aquestive Therapeutics Inc.
  • 4. Ascend Pharmaceuticals LLC
  • 5. Biogen Inc.
  • 6. Biohaven Pharmaceutical Holding Co Ltd
  • 7. BrainStorm Cell Limited
  • 8. Corestem, Inc.
  • 9. Cytokinetics, Incorporated
  • 10. F. Hoffmann-La Roche AG
  • 11. Genervon Biopharmaceuticals, LLC
  • 12. Hackensack Meridian Health, Inc.
  • 13. Implicit Bioscience Ltd.
  • 14. Ionis Pharmaceuticals, Inc.
  • 15. ITF Pharma, Inc.
  • 16. Kringle Pharma, Inc.
  • 17. Mitsubishi Tanabe Pharma Corporation
  • 18. Orion Corporation
  • 19. Orphazyme A/S
  • 20. Otsuka Pharmaceutical Co., Ltd.
  • 21. Pfizer Inc.
  • 22. Sanofi-Aventis Groupe S.A.
  • 23. Sun Pharmaceutical Industries Ltd
  • 24. Treeway B.V.

LIST OF FIGURES

  • FIGURE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023